Reported revenues of $5.7 million in 4Q23, up 77% over prior year
Full year revenues of $18.5 million, up 49% over prior year
Gross Margin of 90% in 4Q23 and 86% for full year
CMS.
A single daily low dose of aspirin significantly reduced hepatic fat fraction and liver transaminase levels in a randomized trial in patients with metabolic-associated steatotic liver disease.
Early uncertainty about the safety of noninterferon antivirals in patients with liver cancer may have contributed to the slow acceptance of direct-acting antiviral agents in this population.
Omega-3 fatty acids downregulate expression of betacellulin in patients with NASH, providing a potential new avenue for prevention and treatment, a study has found.